To function in vivo, RNAs requires a safe, effective and stable delivery system to protect the nucleic acid from degradation, for targeted delivery, and allow uptake into cells and subsequent release. Lipid nanoparticles are the most currently successful platform and have been used for COVID-19 vaccines. TIA facilities can offer expertise and experience in the development and formulation of lipid nanoparticles (LNPs) that enable the clinical delivery of RNA molecules.
Menu
